Skin Fibrosis

Low doses of glucocorticoids added to immunosuppression yield no significant benefit for skin fibrosis in early diffuse cutaneous systemic sclerosis, according to data published in Arthritis Care & Research.

EULAR has released new recommendations on the treatment of systemic sclerosis, advancing new treatments and updated approaches to key manifestations such as skin and lung fibrosis.